GSK, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation join forces to develop oxytocin dry powder inhaler
These press releases are intended for business journalists and analysts/investors
Men aged over 50 are being encouraged to see their doctor if they visit the bathroom more than once during the night. Men’s health experts say that - unbeknown to most men – regular night time trips to the loo can be a key symptom of Benign Prostatic Hyperplasia (BPH) a benign condition caused by an enlarged prostate.
Asthma Awareness Week – Popular recording artist and asthma sufferer Kimbra is joining forces with asthma experts and peak respiratory health groups today to launch the Asthma: Take Control campaign. The national campaign is urging people affected by asthma to commit to following the advice given by their healthcare professional to optimise health outcomes.
GSK today announced it will be closing the Medicines Research Unit at the Prince of Wales Hospital in Sydney.
Australian and New Zealand health innovators encouraged to apply for partnership with GSK to turn their ideas into reality.
Panadol is approved by the TGA for the effective relief of backache. The results of the PACE study are not expected to lead to changes in the current recommendations that paracetamol should remain a first line analgesic in low back pain.
GSK is pleased to announce that BENLYSTA® (belimumab) is now available in Australia for use as an add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard therapy. 1
GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium), a maintenance treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease (COPD), also known as “chronic bronchitis,” “smoker’s cough” or “emphysema”.
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration (TGA) has approved Anoro® Ellipta® (umeclidinium/vilanterol) as a maintenance bronchodilator treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease (COPD) which is also known as “chronic bronchitis,” “smoker’s cough” or emphysema”.
Leaders in Australian poppy production, GSK awarded its top poppy producers at an award dinner held in Launceston last week.
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.